The chemical class known as CLCA5_CLAC5 Inhibitors comprises a specialized group of compounds that interact with and modulate the activity of the CLCA5 protein. As a member of the chloride channel accessory (CLCA) family, CLCA5 is believed to play a role in modulating calcium-activated chloride channels (CaCCs) in specific cellular contexts. Inhibitors within this class are carefully developed to target specific regions or binding sites within CLCA5, with the aim of influencing its functional activity or protein-protein interactions involved in chloride channel regulation. The primary objective of CLCA5_CLAC5 Inhibitors is to fine-tune the intricate regulatory mechanisms related to chloride channel conductance, a critical process that maintains cellular homeostasis and signaling. By selectively engaging CLCA5, these inhibitors have the potential to modulate CaCCs' activity, which plays essential roles in various physiological processes, such as neuronal excitability, smooth muscle contraction, and ion transport across epithelial tissues.
The development and characterization of CLCA5_CLAC5 Inhibitors hold promise in providing deeper insights into the functional roles of CLCA5 within cellular environments. By elucidating the specific effects of CLCA5 inhibition on chloride channel regulation, researchers can gain a more comprehensive understanding of the broader physiological and pathophysiological implications associated with CLCA5 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $32.00 | 3 | |
Niflumic acid is a non-steroidal anti-inflammatory drug (NSAID) that has been found to inhibit CLCA2 activity. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Indomethacin is another NSAID that has been reported to inhibit CLCA2 activity. | ||||||
Benzamil•HCl | 161804-20-2 | sc-201070 | 50 mg | $195.00 | 1 | |
Benzamil is a selective inhibitor of the epithelial sodium channel (ENaC), which has been reported to inhibit CLCA2-mediated chloride transport. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Flufenamic acid is an NSAID that has been shown to inhibit chloride ion channels, including CLCA2. | ||||||
5-Nitro-2-(3-phenylpropylamino)benzoic Acid (NPPB) | 107254-86-4 | sc-201542 sc-201542B sc-201542A | 10 mg 25 mg 50 mg | $109.00 $193.00 $317.00 | 7 | |
NPPB is a compound that has been found to inhibit chloride channels, including CLCA2. | ||||||
CFTR Inhibitor-172 | 307510-92-5 | sc-204680 sc-204680A | 10 mg 50 mg | $168.00 $520.00 | 10 | |
CFTRinh-172 is a selective inhibitor of the CFTR chloride channel, which indirectly affects CLCA2 activity. | ||||||
T16Ainh-A01 | 552309-42-9 | sc-497578 sc-497578A | 10 mg 50 mg | $69.00 $283.00 | ||
T16Ainh-A01 is a selective inhibitor of the calcium-activated chloride channel TMEM16A (ANO1), which shares functional similarities with CLCA2. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
Bumetanide is a loop diuretic that has been reported to inhibit chloride ion transport, potentially affecting CLCA2 activity. | ||||||